May 9th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Investigating Immunotherapy Versus Best Supportive Care in Patients With CRC
February 4th 2019Raymond Wadlow, MD, discusses the results for the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer.
Watch
Grothey Shares Encouraging Data from Lead-In Phase of BEACON CRC Trial
January 24th 2019Axel Grothey, MD, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and anti-EGFR antibody cetuximab in patients with <em>BRAF</em>V600E-mutant metastatic colorectal cancer.
Watch
Direct-to-Consumer Test for Hereditary CRC Syndrome Approved by FDA
January 24th 2019A direct-to-consumer genetic test has been approved by the FDA for providing a risk report on MUTYH-associated polyposis, a hereditary colorectal cancer syndrome, according to 23andMe, the personal genetics company that manufactures the test.<br />
Read More
Promising CheckMate-142 Data for Second-Line Ipilimumab Plus Nivolumab in mCRC
January 22nd 2019Michael J. Overman, MD, discusses the data presented at the 2019 Gastrointestinal Cancers Symposium for the phase II CheckMate-142 in previously treated patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
Watch
Single-Agent Durvalumab Shows Benefit in MSI-H CRC
January 21st 2019Treatment with durvalumab demonstrated objective responses in approximately one-fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer, according to data from 2 preliminary clinical trials.
Read More
OS Increases With Checkpoint Inhibitor Doublet in Advanced Colorectal Cancer
January 21st 2019When durvalumab and tremelimumab were combined with best supportive care, the combination reduced the risk of progression or death by 28% compared with best supportive care alone, according to findings from a phase II clinical trial.
Read More
Triplet Combo Improves Survival for BRAF V600E-Mutant mCRC
January 20th 2019Updated findings from the safety lead-in phase of the BEACON CRC trial showed an estimated survival time beyond historic controls from treatment with a triplet combination of encorafenib, binimetinib, and cetuximab for patients with <em>BRAF </em>V600E-mutant metastatic colorectal cancer.
Read More
Next Steps After Phase III BEACON CRC Trial in mCRC
January 19th 2019Pashtoon M. Kasi, MD, MBBS, MS, discusses how the triplet regimen of the BRAF inhibitor encorafenib, the MEK inhibitor binimetinib, and the EGFR inhibitor cetuximab, will impact the treatment landscape for patients with metastatic colorectal cancer.
Watch
Cancer Death Rates on the Decline, 2019 Cancer Stats Report Shows
January 10th 2019Due to the significant decline in smoking and an increase in advances for early cancer detection and screening, the cancer death rate has declined 27% in the United States from 1991 to 2016, according to the American Cancer Society’s annual report on cancer rates.
Read More
Advice To Community Oncologists Treating Patients With CRC
December 20th 2018Al B. Benson III, MD, FACP, FASCO, professor of medicine at Northwestern University, shares advice to community oncologists treating patients with colorectal cancer. He emphasizes looking carefully at different patient characteristics before making treatment decisions.
Watch
First Patient Enrolled in Phase III Study of Novel Agent Arfolitixorin in mCRC
December 20th 2018The first patient has been enrolled in the pivotal phase III AGENT trial, which is investigating arfolitixorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab compared with FOLFOX plus bevacizumab in patients with metastatic colorectal cancer, according to Isofol Medical AB, the company developing arfolitixorin.
Read More